drugset / Trial / NCT04564066
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.
Timeline
- Start
- 2020-08-18
- Primary completion
- 2020-12-24
- Completion
- 2021-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgartigimod Alfa | Protein / enzyme biologic | — | Intravenous |
Indications
No indication recorded.